Patient-reported outcomes in real-world use of benralizumab in patients with severe eosinophilic asthma in Belgium - BE-REAL

Inclusion Criteria

• • Male or female patients 18 years or older with physician’s confirmed diagnosis of severe, uncontrolled asthma
• • Asthma requiring high dose inhaled corticosteroid plus long-acting β adrenoceptor agonist as maintenance treatment
• • A decreased lung function (FEV1 <80%), demonstrated by spirometry in the 12 months before initiation of treatment
• • Patients need to fulfil one of the criteria:
• - at least 2 hospitalizations or ER treatments for severe asthma during last 12 months, or
• - at least 2 asthma exacerbations during last 12 months (worsening of asthma with need of systemic corticotherapy for at least 3 days for non cortico-dependent patients, and/or an ER visit and or a hospitalization),
• - or cortico-dependent (at least 6 months treatment with OCS at a daily dose of 4 mg or more of methylprednisolone or 5 mg or more of prednisolone for adults)
• • Peripheral blood eosinophil count ≥300cells/μl at initiation of benralizumab treatment and in the year before.
• • Obtained reimbursement for treatment with benralizumab
• • Provision of signed written informed consent form (ICF) indicating that they understand the purpose of the study and procedures required for participation in the study.
• • Patients must be able and willing to read and comprehend written instructions and comprehend and complete the questionnaires required by the protocol.
• • Benralizumab naïve and have not previously received benralizumab prior to the start of this study.